TG Therapeutics Inc (TGTX)
Cash ratio
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 195,822 | 82,910 | 75,477 | 92,933 | 150,902 | 97,009 | 61,469 | 102,304 | 109,860 | 147,073 | 185,676 | 298,887 | 326,512 | 401,707 | 471,514 | 553,439 | 254,154 | 260,512 | 52,051 | 112,637 |
Short-term investments | US$ in thousands | 145,219 | 134,342 | 134,308 | 124,575 | 78,257 | 47,896 | 78,241 | 59,374 | 66,082 | 48,636 | 47,525 | 15,876 | 30,338 | 41,752 | 52,334 | 51,987 | 46 | 15,058 | 26,284 | 27,798 |
Total current liabilities | US$ in thousands | 125,114 | 108,664 | 99,684 | 53,720 | 57,678 | 72,667 | 63,076 | 53,201 | 36,447 | 43,326 | 54,656 | 65,384 | 87,655 | 87,551 | 92,494 | 87,554 | 77,670 | 67,537 | 63,118 | 84,449 |
Cash ratio | 2.73 | 2.00 | 2.10 | 4.05 | 3.97 | 1.99 | 2.21 | 3.04 | 4.83 | 4.52 | 4.27 | 4.81 | 4.07 | 5.07 | 5.66 | 6.91 | 3.27 | 4.08 | 1.24 | 1.66 |
September 30, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($195,822K
+ $145,219K)
÷ $125,114K
= 2.73
The cash ratio of TG Therapeutics Inc has shown some fluctuations over the past few quarters. The cash ratio measures a company's ability to cover its short-term liabilities with its cash and cash equivalents.
Looking at the data, the cash ratio has generally been above 1, indicating that the company has sufficient cash to cover its short-term obligations. The cash ratio has ranged from 1.24 to 6.91 over the past few years, with the highest values indicating a stronger ability to meet short-term obligations with cash on hand.
Specifically, the cash ratio increased from 1.66 in March 2020 to 6.91 in December 2020, showing a significant improvement in liquidity. However, there were fluctuations in the subsequent quarters, with the ratio ranging between 2.00 and 4.83.
Overall, the cash ratio of TG Therapeutics Inc suggests that the company has generally maintained a healthy level of liquidity, enabling it to meet its short-term obligations comfortably.
Peer comparison
Sep 30, 2024